Abstract
The discovery of compounds that bind and inhibit the function of microtubules dates back many centuries. The first compound to be used medicinally in humans, ultimately identified to have anti-microtubule properties, was colchicine. Colchicine, extracted from the plant Colchicum autumnale, was first administered to humans with gout in the sixth century A.D. [1]. After it was identified that colchicine blocked cells in metaphase, the compound became an important tool in the study of the cell cycle and mitosis [2].
There is no subject so old that something new cannot be said about it.
Dostoyevsky, A Diary of a Writer (1876), 3, July–August
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hastie SB (1991) Interactions of colchicine with tubulin. Pharmacol Ther 51(3):377–401
Malkinson F (1981) Colchicine new uses for an old, old drug. Arch Dermatol 118:453–457
Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17(3):1061–1070
Dustin P (1984) Microtubules, 2nd edn. Springer, New York
Hyams JL, Lloyd CW (1993) Microtubules. Wiley-Liss, New York
Baker TS, Amos LA (1978) Structure of the tubulin dimer in zinc-induced sheets. J Mol Biol 123(1):89–106
Lewis SG, Gilmartin ME, Hall JL, Cowan NJ (1985) Three expressed sequences within the human btea-tubulin multigene family each define a distinct isotyope. J Mol Biol 182(1):11–20
Dobner PR et al (1987) Alternative 5ʹ exons either provide or deny an initiator methionine codon to the same alpha-tubulin coding region. Nucleic Acids Res 15(1):199–218
Amos LA, Baker TS (1979) The three-dimensional structure of tubulin protofilaments. Nature 279(5714):607–612
Schulze E et al (1987) Posttranslational modification and microtubule stability. J Cell Biol 105(5):2167–2177
Vallee RB, Bloom GS, Theurkauf WE (1984) Microtubule-associated proteins: subunits of the cytomatrix. J Cell Biol 99(1 Pt 2):38s–44s
Desai A, Mitchison TJ (1997) Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 13:83–117
Wilson L, Panda D, Jordan MA (1999) Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct Funct 24(5):329–335
Rowinsky, ED, Donehower RC (1996) Antimicrotubule agents In: BA Chabner, Longo DL (eds) Cancer chemotherapy and biotherapy; principles and practice, 2nd edn. Lippincott-Raven, Philadelphia, New York
Wani MC et al (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325–2327
Wall ME and Wani MC (1995) Camptothecin and taxol: discovery to clinic – thirteenth Bruce F. Cain memorial award lecture. Cancer Res 55(4):753–760
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665–667
Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77(3):1561–1565
Cortes JE, Pazdur R (1995) Docetaxel. J Clin Oncol 13(10):2643–2655
Gligorov J, Lotz JP (2004) Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl 2):3–8
Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332(15):1004–1014
Nogales E et al (1999) High-resolution model of the microtubule. Cell 96(1):79–88
De Brabander M et al (1981) Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 78(9):5608–5612
Peyrot V, Briand C (1992) c. Biophysical characterization of the assembly of purified tubulin induced by Taxol and Taxotere (RP 56976) in Second Interface of Clinical and Laboratory Responses to Anticancer Drugs: Drugs and Microtubules. Marseille, France
Derry WB, Wilson L, Jordan MA (1995) Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34(7):2203–2211
Wilson L (1975) Microtubules as drug receptors: pharmacological properties of microtubule protein. Annu NY Acad Sci 253:213
Rowinsky EK et al (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48(14):4093–4100
Roberts RL et al (1982) Effects of taxol on human neutrophils. J Immunol 129(5):2134–2141
Ding AH et al (1990) Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 248(4953):370–372
Haldar S, Jena N, Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92(10):4507–4511
Belotti D et al (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2(11):1843–1849
Hennequin C, Giocanti N, Favaudon V (1995) S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71(6):1194–1198
Riou JP, Petitgenet O, Combeau C et al (1994) Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc AM Assoc Can Res 35:385:Abstract #2292
Maguire HC, Ettore VL (1967) Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 48:39–43
Berd D et al (1982) Augmentation of the human immune response by cyclophosphamide. Cancer Res 42:4862–4866
Berd D, Maguire HC, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceeded by cyclophosphamide. Cancer Res 46:2572–2577
Machiels JP et al (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61(9):3689–3697
Arlen, PM et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4):1260–1269
Cabral F et al (1983) Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 97(1):30–39
Giannakakou P et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272(27):17118–17125
Ranganathan S et al (1996) Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56(11):2584–2589
Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221(4617):1285–1288
Ling V (1992) Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer 69(10):2603–2609
Horwitz SBL, Liao LL, Greenberger L (1989) Mode of action of taxol and characterization of a multidrug-resistant cell line resistant to taxol. In: Kessel D (ed) Resistance to antineoplastic drugs. CRC, Boca Raton, FL, pp 109–126
Masuda A et al (2003) Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 163(3):1109–1116
Rudner AD, Murray AW (1996) The spindle assembly checkpoint. Curr Opin Cell Biol 8(6):773–780
Rouzier R et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102(23):8315–8320
Wagner P et al (2005) Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4(9):1149–1152
Kar S et al (2003) Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. Embo J 22(1):70–77
Ramanathan B et al (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65(18):8455–8460
Van Poznak C et al (2002) Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 20(9):2319–2326
Schmidt M et al (2003) p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 129(5):295–302
Slamon DJ et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
Slamon DJ et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712
Gandour-Edwards R et al (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95(5):1009–1015
Yu D et al (1996) Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13(6):1359–1365
Perez-Soler R et al (2000) Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6(12):4932–4938
Witters LM et al (2003) Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Am J Clin Oncol 26(1):50–54
O’Brien ML, Tew KD (1996) Glutathione and related enzymes in multidrug resistance. Eur J Cancer 32A(6):967–978
O’Brien ML et al (1999) Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 291(3):1348–1355
Arai T et al (2008) Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 34(7):734–738
Waris G, Ahsan H (2006) Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 5:14
Alexandre J et al (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119(1):41–48
Alexandre J et al (2006) Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 98(4):236–244
Alexandre J et al (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67(8):3512–3517
Rowinsky EK et al (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19(6):646–662
Eisenhauer EA et al (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12(12):2654–2666
Sparreboom A et al (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56(9):2112–2115
Gianni L et al (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13(1):180–190
Sparreboom A et al (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59(7):1454–1457
Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99–114
Desai NP, Louie L, Ron N, Magdassi S, Soon-Shiong P (2000) Proetin-bound nanoparticles for drug delivery of paclitaxel. Trans World Biomater Congr 1:199
Ibrahim NK et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038–1044
Vorum H (1999) Reversible ligand binding to human serum albumin. Theoretical and clinical aspects. Dan Med Bull 46(5):379–399
John TA et al (2003) Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 284(1):L187–L196
Rempel SA, Ge S, Gutierrez JA (1999) SPARC: a potential diagnostic marker of invasive meningiomas. Clin Cancer Res 5(2):237–241
Schnitzer JE, Oh P (1992) Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am J Physiol 263(6 Pt 2):H1872–H1879
Porter PL et al (1995) Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 43(8):791–800
Thomas R et al (2000) Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 6(3):1140–1149
Brown TJ et al (1999) Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol 75(1):25–33
Ledda F et al (1997) The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108(2):210–214
Schilling U, Friedrich EA, Sinn H (1992) Design of compounds having enhanced tumor uptale, using serum albumin as a carrier: part II In vivo studies. Int J Rad Appl Instrum B 19:685–695
Desai N et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324
Cresteil T et al (1994) Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54(2):386–392
Harris JW et al (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54(15):4026–4035
Rowinsky EK et al (1989) Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49(16):4640–4647
Gelderblom H et al (2003) Distribution of paclitaxel in plasma and cerebrospinal fluid. Anticancer Drugs 14(5):365–368
ten Tije AJ et al (2004) Limited cerebrospinal fluid penetration of docetaxel. Anticancer Drugs 15(7):715–718
Forastiere AA et al (2001) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: eastern cooperative oncology group study E1393. J Clin Oncol 19(4):1088–1095
Roth BJ et al (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the eastern cooperative oncology group. J Clin Oncol 12(11):2264–2270
Van Poznak C, Seidman AD (2002) Critical review of current treatment strategies for advanced hormone insensitive breast cancer. Cancer Invest 20(Suppl 2):1–14
Eniu A, Palmieri FM, Perez EA (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10(9):665–685
Sikov WM, Akerly W, Kahanic S et al (2002) Multicenter, 3-armed randomized study of high-dose weekly paclitaxel, (HWDP) versus standard-dose weekly paclitaxel (SWDP) for metastatic breast cancer, (MBC) Proc ASCO 21:34a
Akerley W et al (1997) Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol 24(4 Suppl 12):S12–10–S12–13
Perez EA et al (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19(22):4216–4223
Panday VR et al (1998) Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer. Anticancer Drugs 9(8):665–673
Schwonzen M, Kurbacher CM, Mallmann P (2000) Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 11(9):681–685
Frasci G et al (1998) Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat 49(1):13–26
Spano JP et al (2004) Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. Am J Clin Oncol 27(3):317–321
Seidman AD et al (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19(10):2587–2595
Frasci G et al (2006) Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs. triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer 95(8):1005–1012
Ford HE et al (2006) A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemother Pharmacol 58(6):809–815
Burstein HJ et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18(6):1212–1219
Ramos M et al (2003) Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 15(2):192–197
Ito Y et al (2001) Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer. Int J Clin Oncol 6(5):242–247
Wenzel C et al (2002) Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 50(2):155–159
Frasci G et al (2000) Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 11(3):367–371
Kornek GV et al (2001) Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 19(3):621–627
Esteva FJ et al (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7):1800–1808
Tedesco KL et al (2004) Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22(6):1071–1077
Raff JP et al (2004) Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 4(6):420–427
Wenzel C et al (2004) Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 130(7):400–404
Nyman DW et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23(31):7785–7793
Moreno-Aspitia A, Perez EA (2005) North Central Cancer Treatment Group N0531: phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin Breast Cancer 6(4):361–364
Stinchcombe TE et al (2007) Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane((R))) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 60(5):759–766
Rowinsky EK et al (1991) Cardiac disturbances during the administration of taxol. J Clin Oncol 9(9):1704–1712
Shenkier T, Gelmon K (1994), Paclitaxel and radiation recall dermatitis [Letter]. J Clin Oncol 12:439
Francis PA et al (1994) Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12(6):1232–1237
Extra JM et al (1993) Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53(5):1037–1042
Pazdur R et al (1992) Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 84(23):1781–1788
Bissett D et al (1993) Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53(3):523–527
Green MR et al (2006) Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17(8):1263–1268
Paridaens R et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18(4):724–733
Sledge GW et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 21(4):588–592
Chan S et al (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17(8):2341–2354
Ibrahim NK et al (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019–6026
Gradishar WJ et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803
Biganzoli L et al (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20(14):3114–3121
Jassem J et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19(6):1707–1715
Luck H, Thomssen C, Untch M, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Moebus V, Steinfeld D, Bauknecht T, Schroeder W, Jackisch C (2000) Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) Vs Epirubicin/Cyclophosphamide (EC). A Study of the Ago Breast Cancer Group. Proc ASCO 19:73a
Crown J, O’Leary M, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9(Suppl 2):24–32
Bonneterre J et al (2004) Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 91(8):1466–1471
Mackey JR, Paterson A, Drix LY et al (2002) Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). in Proc ASCO 21:35a
Nabholtz JM et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21(6):968–975
Bontenbal M et al (2005) Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch community setting trial for the clinical trial group of the comprehensive cancer centre. J Clin Oncol 23(28):7081–7088
Blum JL et al (2007) Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 7(11):850–856
Roy V et al (2009) Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 20(3):449–453
Link JS et al (2007) Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 7(10):779–783
Untch M, Konecny G, Ditsch N et al (2002) Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc ASCO 21:133a
Green MC et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983–5992
Bear HD et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24(13):2019–2027
Hutcheon AW, Heys SD, Sarkar TK (2003) Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat 79(Suppl 1):S19–S24
von Minckwitz G et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German breast group. J Clin Oncol 23(12):2676–2685
Evans TR et al (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 23(13):2988–2995
Henderson IC et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976–983
Mamounas EP et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23(16):3686–3696
Martin M et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313
Pienta KJ (2001) Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 28(4 Suppl 15):3–7
Raghavan D (2004) Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet! Br J Cancer 91(6):1003–1004
Canil CM, Tannock IF (2004) Is there a role for chemotherapy in prostate cancer? Br J Cancer 91(6):1005–1011
Tannock IF et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512
Petrylak DP et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520
Berthold DR, Pond G, de Wit R et al (2007) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. Proc ASCO Abstract #147 Prostate Cancer Symposium
Ramalingam S, Belani C (2008) Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13(Suppl 1):5–13
Ramalingam S, Sandler AB (2006) Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 11(6):655–665
Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550
Stinchcombe TE, Socinski MA (2008) Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13(Suppl 1):28–36
Hanna N et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597
Shepherd FA et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10):2095–2103
Fossella FV et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18(12):2354–2362
Rizvi NA et al (2008) Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 26(4):639–643
McGuire WP et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1):1–6
Ozols RF et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21(17):3194–3200
Armstrong DK et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43
Teneriello MG et al (2009) Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 27(9):1426–1431
Bourhis J (2005) New approaches to enhance chemotherapy in SCCHN. Ann Oncol 16(Suppl 6):vi20–vi24
Amato RJ (2005) Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16(1):7–15
Roth AD, Ajani J (2003) Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 14(Suppl 2):ii41–ii44
Scheithauer W (2004) Esophageal cancer: chemotherapy as palliative therapy. Ann Oncol 15(Suppl 4):iv97–iv100
Galsky MD (2005) The role of taxanes in the management of bladder cancer. Oncologist 10(10):792–798
Hennenfent KL, Govindan R (2006) Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 17(5):735–749
Gerth K et al (1996) Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 49(6):560–563
Bollag DM et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55(11):2325–2333
Kowalski RJ, Giannakakou P, Hamel E (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 272(4):2534–2541
Kamath K, Jordan MA (2003) Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 63(18):6026–6031
Nettles JH et al (2004) The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science 305(5685):866–869
Bode CJ et al (2002) Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 41(12):3870–3874
Cortes J, Baselga J (2007) Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12(3):271–280
Wartmann M, Altmann KH (2002) The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2(1):123–148
Nicolaou KC et al (1997) Synthesis of epothilones A and B in solid and solution phase. Nature 387(6630):268–272
Lee FY et al (2001) BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7(5):1429–1437
Chou TC et al (1998) Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 95(16):9642–9647
Newman RA et al (2001) Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 48(4):319–326
Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8(3):161–170
Giannakakou P et al (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97(6):2904–2909
Verrills NM et al (2003) Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 10(7):597–607
Forster M et al (2007) A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res 13(14):4178–4184
Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22(10):2015–2025
Mani S et al (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10(4):1289–1298
Abraham J et al (2003) Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21(9):1866–1873
McDaid HM et al (2002) Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 8(7):2035–2043
Spriggs D, Soignet SA, Bienvenu B et al (2001) Phase I first in man study of epothilone B analog BMS-247550 in patients with advanced cancer. Proc ASCO 20:108a, Abstract #428
Gadgeel SM et al (2005) Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 11(17):6233–6239
Zhuang SH et al (2005) A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 103(9):1932–1938
Awada A, Bleiberg H, de Valeriola D et al (2001) Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients with advanced solid tumors. Proc ASCO 20:103a, Abstract #421
Hao D, Hammond LA, deBono JS et al (2002) Continuous weekly administration of the epothilone-B derivative, BMS-247550 (NSC710428): a phase I and pharmacokinetic study. Proc ASCO 21:103a, Abstract #411
Burris HA 3rd, Jones S et al (2002) Phase I study of the novel epothilone BMS-247550 administered weekly in patients with advanced malignancies. Proc ASCO 21:103a, Abstract #412a
Plummeer R, Molife R, Verrill M et al (2002) Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 21:78b
Smaletz O et al (2003) Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 14(10):1518–1524
Galsky MD et al (2005) Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23(7):1439–1446
Gianni L (2007) Ixabepilone and the narrow path to developing new cytotoxic drugs. J Clin Oncol 25(23):3389–3391
Perez EA et al (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25(23):3407–3414
Denduluri N et al (2007) Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25(23):3421–3427
Roche H et al (2007) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25(23):3415–3420
Vansteenkiste J et al (2007) Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 25(23):3448–3455
Thomas ES et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25(33):5210–2517
Low JA et al (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23(12):2726–2734
Roche H, Cure H, Bunnell C et al (2003) A phase II study of epothilone analog BMS-247550 in patients with metastatic breast cancer previously treated with an anthracycline. Proc ASCO 24:586a
Llombart A, Baselga J, Manikhas G et al (2005) Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer: preliminary efficacy and safety data. Proc ASCO 24:586a
Chen TL, Calvert AH et al (2002) Pharmacokinetics of EPO906 in cancer patients receiving EPO906 by short intravenous infusion once every 3 weeks. Proc ASCO 21:91a, Abstract #413
Rubin, EH, Siu, LL, Beers S et al (2001) A phase I and pharmacokindtic trial of weekly epothiline B in patients with advanced malignancies. Proc ASCO 20:68a, Abstract #270
Calvert AH, O’Neill V, Twelves C et al (2001) A phase I and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid malignancies. Proc ASCO 20:108a, Abstract #429
Ten Bokkel Huinink WW et al (2009) Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 27(19):3097–3103
Forster M, Kaye S, Oza A, Sklenar I, Johri A, Cheung W, Zaknoen S, Gore M (2007) A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res 13(14):4178–4184
Schelman W et al (2008) A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother Pharmacol 62(4):727–733
Mekhail T et al (2003) Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc ASCO 22:130, Abstract #515
Piro LD, Rosen LS, Parson M et al (2003) KOS-862 (Epothilone D) a comparison of two schedules in patients with advanced malignancies. Proc ASCO 22:135, Abstract #539
Spriggs D, Pezzulli S et al (2003) KOS-862 (epothilone D): phase I dose escalating and pharmacokinetic study in patients with advanced malignancies. Proc ASCO 22:223, Abstract #894
Cortes J, Gomez P et al (2006) A phase I trial of weekly combination KOS-862 (epothilone D) and trastuzumab in HER-2 overexpressing melignancies. Proc ASCO 25:2028a
Schmid P, Kuehnhardt D et al (2005) A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. Proc ASCO 24:2051a
Arnold D et al (2009) Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 101(8):1241–1247
Rubin EH et al (2005) Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 23(36):9120–9129
Sessa C, Malossi A et al (2003) Phase I and pharmacokinetic study of the novel epothilone BMS-31–705 in patients with advanced solid cancer. Proc ASCO 22:519a
Sessa C et al (2007) Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 18(9):1548–1553
Holen KZD, Hannah AL et al (2004) Phase I study using continuous intravenous KOS-862 (Epothilone D) in patients with solid tumors. Proc ASCO 23:2024a
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
McClay, E.F. (2011). Taxanes and Epothilones in Cancer Treatment. In: Minev, B. (eds) Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Cancer Growth and Progression, vol 13. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9704-0_3
Download citation
DOI: https://doi.org/10.1007/978-90-481-9704-0_3
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9703-3
Online ISBN: 978-90-481-9704-0
eBook Packages: MedicineMedicine (R0)